Clinical Trial Search

Primary: Change From Baseline in Glycosylated Hemoglobin (%) — -0.92; -0.31 change from baseline in A1c (%)

Primary: State-Trait Anxiety Inventory (STAI Y1) — -6.4; -5.8; -4.1; -5.0 units on a scale

Primary: Weight — 226.54; 225.46; 218.19; 225.63 pounds (lbs) — p=.025

Primary: Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints — 30; 28; 0; 0 Participants

Primary: Hypoglycemia < 70 mg/dL — 3.6; 2.6; 3.2 percentage of time

Primary: EQ Visual Analog Scale (EQVAS) — 64.6; 66.8; 73.8; 67.0 score on a scale

Primary: Pain Occurence — 4.6; 4.6 units on Mobid-2 pain scale ( 0-10)

Primary: Postural Control-Stability Index in Solid Surface - Eyes Open — 1.06; 2.00 score on a scale — p=0.866

Primary: Percentage of Participants With a ≥15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic…

Primary: Dynamic Cerebral Autoregulation Parameter: Phase Difference(PD) in Degree — 45.87 degree

Primary: Measurement of Treatment Efficacy Determined by DSAP-GASI Score (Disseminated Actinic Porokeratosis General Assessment Severity Index) — 50.0; 51.4 Percent decrease in…

Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 — 11.5; 33.1 percentage of participants — p=<0.0001

Primary: Patient-reported Quality of Life (QOL): Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) — 94.69; 90.09 score on a scale

Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml

Primary: Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24 — -20.93; 8.13; -18.33; 21.13 percent…